Search

Your search keyword '"Ahluwalia, Manmeet"' showing total 710 results
Start Over Author "Ahluwalia, Manmeet" Language english
710 results on '"Ahluwalia, Manmeet"'

1. Leptomeningeal metastatic disease: new frontiers and future directions

Author

Ozair, Ahmad, Wilding, Hannah, Bhanja, Debarati, Mikolajewicz, Nicholas, Glantz, Michael, Grossman, Stuart A., Sahgal, Arjun, Le Rhun, Emilie, Weller, Michael, Weiss, Tobias, Batchelor, Tracy T., Wen, Patrick Y., Haas-Kogan, Daphne A., Khasraw, Mustafa, Rudà, Roberta, Soffietti, Riccardo, Vollmuth, Philipp, Subbiah, Vivek, Bettegowda, Chetan, Pham, Lily C., Woodworth, Graeme F., Ahluwalia, Manmeet S., and Mansouri, Alireza

Published
2025
Full Text
View/download PDF

4. Multi-institutional report of trastuzumab deruxtecan and stereotactic radiosurgery for HER2 positive and HER2-low breast cancer brain metastases

Author

Khatri, Vaseem M., Mestres-Villanueva, Mariella A., Yarlagadda, Sreenija, Doniparthi, Ajay, Smith, David B., Nakashima, Justyn Y., Bryant, John M., Zhao, Dekuang, Upadhyay, Rituraj, Mills, Matthew N., Oliver, Daniel E., Yu, Hsiang-Hsuan Michael, Palmer, Joshua D., Williams, Nicole O., Mahtani, Reshma L., Ahluwalia, Manmeet S., Soliman, Hatem H., Han, Hyo S., Soyano, Aixa E., Kim, Youngchul, Kotecha, Rupesh, Beyer, Sasha J., and Ahmed, Kamran A.

Published
2024
Full Text
View/download PDF

7. Comparative evaluation of outcomes amongst different radiosurgery management paradigms for patients with large brain metastasis

Author

Kutuk, Tugce, Zhang, Yanjia, Akdemir, Eyub Yasar, Yarlagadda, Sreenija, Tolakanahalli, Ranjini, Hall, Matthew D., La Rosa, Alonso, Wieczorek, DJay J., Lee, Yongsook C., Press, Robert H., Appel, Haley, McDermott, Michael W., Odia, Yazmin, Ahluwalia, Manmeet S., Gutierrez, Alonso N., Mehta, Minesh P., and Kotecha, Rupesh

Published
2024
Full Text
View/download PDF

8. A brave new framework for glioma drug development

Author

Hotchkiss, Kelly M, Karschnia, Philipp, Schreck, Karisa C, Geurts, Marjolein, Cloughesy, Timothy F, Huse, Jason, Duke, Elizabeth S, Lathia, Justin, Ashley, David M, Nduom, Edjah K, Long, Georgina, Singh, Kirit, Chalmers, Anthony, Ahluwalia, Manmeet S, Heimberger, Amy, Bagley, Stephen, Todo, Tomoki, Verhaak, Roel, Kelly, Patrick D, Hervey-Jumper, Shawn, de Groot, John, Patel, Anoop, Fecci, Peter, Parney, Ian, Wykes, Victoria, Watts, Colin, Burns, Terry C, Sanai, Nader, Preusser, Matthias, Tonn, Joerg Christian, Drummond, Katharine J, Platten, Michael, Das, Sunit, Tanner, Kirk, Vogelbaum, Michael A, Weller, Michael, Whittle, James R, Berger, Mitchel S, and Khasraw, Mustafa

Published
2024
Full Text
View/download PDF

11. Immune checkpoint inhibition and single fraction stereotactic radiosurgery in brain metastases from non-small cell lung cancer: an international multicenter study of 395 patients

Author

Lehrer, Eric J., Khosla, Atulya A., Ozair, Ahmad, Gurewitz, Jason, Bernstein, Kenneth, Kondziolka, Douglas, Niranjan, Ajay, Wei, Zhishuo, Lunsford, L. Dade, Mathieu, David, Trudel, Claire, Deibert, Christopher P., Malouff, Timothy D., Ruiz-Garcia, Henry, Peterson, Jennifer L., Patel, Samir, Bonney, Phillip, Hwang, Lindsay, Yu, Cheng, Zada, Gabriel, Picozzi, Piero, Franzini, Andrea, Attuati, Luca, Prasad, Rahul N., Raval, Raju R., Palmer, Joshua D., Lee, Cheng-chia, Yang, Huai-che, Fakhoury, Kareem R., Rusthoven, Chad G., Dickstein, Daniel R., Sheehan, Jason P., Trifiletti, Daniel M., and Ahluwalia, Manmeet S.

Published
2023
Full Text
View/download PDF

14. 18F-fluciclovine PET/CT to distinguish radiation necrosis from tumor progression for brain metastases treated with radiosurgery: results of a prospective pilot study

Author

Tom, Martin C., DiFilippo, Frank P., Jones, Stephen E., Suh, John H., Obuchowski, Nancy A., Smile, Timothy D., Murphy, Erin S., Yu, Jennifer S., Barnett, Gene H., Angelov, Lilyana, Mohammadi, Alireza M., Huang, Steve S., Wu, Guiyun, Johnson, Scott, Peereboom, David M., Stevens, Glen H. J., Ahluwalia, Manmeet S., and Chao, Samuel T.

Published
2023
Full Text
View/download PDF

19. SerpinB3 drives cancer stem cell survival in glioblastoma

Author

Lauko, Adam, Volovetz, Josephine, Turaga, Soumya M., Bayik, Defne, Silver, Daniel J., Mitchell, Kelly, Mulkearns-Hubert, Erin E., Watson, Dionysios C., Desai, Kiran, Midha, Manav, Hao, Jing, McCortney, Kathleen, Steffens, Alicia, Naik, Ulhas, Ahluwalia, Manmeet S., Bao, Shideng, Horbinski, Craig, Yu, Jennifer S., and Lathia, Justin D.

Published
2022
Full Text
View/download PDF

20. Cognitive function after concurrent temozolomide-based chemoradiation therapy in low-grade gliomas

Author

Park, Deborah Y., Tom, Martin C., Chen, Yanwen, Tewari, Surabhi, Ahluwalia, Manmeet S., Yu, Jennifer S., Chao, Samuel T., Suh, John H., Peereboom, David M., Stevens, Glen H. J., Barnett, Gene H., Angelov, Lilyana, Mohammadi, Alireza, Hogan, Thomas, Kissel, Courtney, Lapin, Brittany, Schuermeyer, Isabel, Parsons, Michael W., Naugle, Richard, and Murphy, Erin S.

Published
2022
Full Text
View/download PDF

23. Emerging Therapies for Brain Metastases in NSCLC, Breast Cancer, and Melanoma: A Critical Review.

Author

Podder, Vivek, Ranjan, Tulika, Gowda, Maya, Camacho, Alejandra M., and Ahluwalia, Manmeet S.

Abstract

Purpose of Review: Advancements in precision medicine have shifted the treatment paradigm of brain metastases (BM) from non-small cell lung cancer (NSCLC), breast cancer, and melanoma, especially through targeted therapies focused on specific molecular drivers. These novel agents have improved outcomes by overcoming challenges posed by the blood-brain barrier (BBB) and resistance mechanisms, enabling more effective treatment of BM. Recent Findings: In NSCLC, therapies such as osimertinib have improved efficacy in treating EGFR-mutant BM, with emerging combinations such as amivantamab and lazertinib offering promising alternatives for patients resistant to frontline therapies. In HER2-positive breast cancer, significant advancements with tucatinib and trastuzumab deruxtecan (T-DXd) have transformed the treatment landscape, achieving improved survival and intracranial control in patients with BM. Similarly, in triple-negative breast cancer (TNBC), novel therapies such as sacituzumab govitecan (SG) and datopotamab deruxtecan (Dato-DXd) offer new hope for managing BM. For melanoma, the combination of immune checkpoint inhibitors such as nivolumab and ipilimumab has proven effective in enhancing survival for patients with BM, both in BRAF-mutant and wild-type cases. Summary: Developing targeted therapies penetrating the BBB has revolutionized BM treatment by targeting key drivers like EGFR, ALK, HER2, and BRAF. Despite improved survival, challenges persist, particularly for patients with resistant genetic alterations. Future research should optimise combination therapies, overcome resistance, and refine treatment sequencing. Continued emphasis on personalized, biomarker-driven approaches offers the potential to further improve outcomes, even for complex cases. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

24. Evaluating the Safety of Immune Checkpoint Inhibitors and Combination Therapies in the Management of Brain Metastases: A Comprehensive Review.

Author

Podder, Vivek, Ranjan, Tulika, Margolin, Kim, Maharaj, Arun, and Ahluwalia, Manmeet Singh

Subjects
THERAPEUTIC use of antineoplastic agents, COMBINATION drug therapy, SYNDROMES, RISK assessment, PATIENT safety, NEUROTOXICOLOGY, RADIOSURGERY, TREATMENT effectiveness, IMMUNE checkpoint inhibitors, CANCER chemotherapy, COMBINED modality therapy, PATIENT monitoring, INDIVIDUALIZED medicine, BRAIN tumors, DISEASE risk factors
Abstract

Simple Summary: Immune checkpoint inhibitors (ICIs) have become an important treatment for patients with brain metastases from cancers like lung cancer, melanoma, and breast cancer. While ICIs can improve survival, they can also cause immune-related adverse events (irAEs), affecting various organs, including the brain. This review discusses the safety of ICIs when used alone or in combination with other treatments like chemotherapy and radiosurgery. We explain how irAEs occur, their effects on different parts of the body, and how to manage them. Careful monitoring and treatment planning are essential to ensure the best outcomes for patients with brain metastases. Brain metastases (BM) are a frequent and severe complication in patients with lung cancer, breast cancer, and melanoma. Immune checkpoint inhibitors (ICIs) have become a crucial treatment option for BM, whether used alone or in combination with chemotherapy and stereotactic radiosurgery (SRS). However, ICIs are associated with immune-related adverse events (irAEs) that can affect multiple organ systems, complicating their use in BM patients. This review examines the mechanisms of irAEs and their effects on different organs and evaluates the safety of ICIs across various treatment strategies for BM. Our analysis indicates that ICIs significantly improve survival and disease control in BM patients, but their use increases the risk of irAEs, including dermatologic, gastrointestinal, endocrine, pulmonary, and neurologic toxicities. Neurotoxic events, particularly treatment-associated brain necrosis (TABN) and encephalitis, are more common in BM patients. While the overall incidence of irAEs is similar between patients with and without BM, the neurotoxicity risk is higher in the BM population. Combining ICIs with chemotherapy and SRS enhances efficacy but also heightens the risk of adverse events across organ systems. ICIs offer substantial benefits for BM patients but require careful management to mitigate the risks of irAEs. Close patient monitoring, individualized treatment protocols, and prompt intervention are essential for optimizing the outcomes. Future research should focus on refining combination strategies and improving the management of irAEs, particularly neurotoxicity, to maximize therapeutic benefits for BM patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Financial barriers and inequity in medical education in India: challenges to training a diverse and representative healthcare workforce.

Author

Rahman, Faique, Bhat, Vivek, Ozair, Ahmad, Detchou, Donald K. E., and Ahluwalia, Manmeet S.

Subjects
PUBLIC health infrastructure, RESIDENTS (Medicine), RESOURCE-limited settings, MEDICAL education, HEALTH equity
Abstract

India has been historically challenged by an insufficient and heterogeneously clustered distribution of healthcare infrastructure. While resource-limited healthcare settings, such as major parts of India, require multidisciplinary approaches for improvement, one key approach is the recruitment and training of a healthcare workforce representative of its population. This requires overcoming barriers to equity and representation in Indian medical education that are multi-faceted, historical, and rooted in inequality. However, literature is lacking regarding the financial or economic barriers, and their implications on equity and representation in the Indian allopathic physician workforce, which this review sought to describe. Keyword-based searches were carried out in PubMed, Google Scholar, and Scopus in order to identify relevant literature published till November 2023. This state-of-the-art narrative review describes the existing multi-pronged economic barriers, recent and forthcoming changes deepening these barriers, and how these may limit opportunities for having a diverse workforce. Three sets of major economic barriers exist to becoming a specialized medical practitioner in India – resources required to get selected into an Indian medical school, resources required to pursue medical school, and resources required to get a residency position. The resources in this endeavor have historically included substantial efforts, finances, and privilege, but rising barriers in the medical education system have worsened the state of inequity. Preparation costs for medical school and residency entrance tests have risen steadily, which may be further exacerbated by recent major policy changes regarding licensing and residency selection. Additionally, considerable increases in direct and indirect costs of medical education have recently occurred. Urgent action in these areas may help the Indian population get access to a diverse and representative healthcare workforce and also help alleviate the shortage of primary care physicians in the country. Discussed are the reasons for rural healthcare disparities in India and potential solutions related to medical education. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Executive summary of American Radium Society’s appropriate use criteria for the postoperative management of lower grade gliomas

Author

Tom, Martin C., Milano, Michael T., Chao, Samuel T., Soltys, Scott G., Knisely, Jonathan P.S., Sahgal, Arjun, Nagpal, Seema, Lo, Simon S., Jabbari, Siavash, Wang, Tony J.C., Ahluwalia, Manmeet S., Simonson, Marian, Palmer, Joshua D., Gephart, Melanie Hayden, Halasz, Lia M., Garg, Amit K., Chiang, Veronica L.S., and Chang, Eric L.

Published
2022
Full Text
View/download PDF

32. Author Correction: Neutrophil to lymphocyte ratio influences impact of steroids on efficacy of immune checkpoint inhibitors in lung cancer brain metastases

Author

Lauko, Adam, Thapa, Bicky, Sharma, Mayur, Muhsen, Baha’eddin A., Barnett, Addison, Rauf, Yasmeen, Borghei-Razavi, Hamid, Tatineni, Vineeth, Patil, Pradnya, Mohammadi, Alireza, Chao, Samuel, Murphy, Erin S., Angelov, Lilyana, Suh, John, Barnett, Gene H., Nowacki, Amy S., Pennell, Nathan, and Ahluwalia, Manmeet S.

Published
2022
Full Text
View/download PDF

34. Quality of life following concurrent temozolomide-based chemoradiation therapy or observation in low-grade glioma

Author

Park, Deborah Y., Tom, Martin C., Wei, Wei, Tewari, Surabhi, Ahluwalia, Manmeet S., Yu, Jennifer S., Chao, Samuel T., Suh, John H., Peereboom, David, Stevens, Glen H. J., Barnett, Gene H., Angelov, Lilyana, Mohammadi, Alireza M., Hogan, Thomas, Kissel, Courtney, Lapin, Brittany, Schuermeyer, Isabel, Parsons, Michael W., Naugle, Richard, and Murphy, Erin S.

Published
2022
Full Text
View/download PDF

36. Toward standardized brain tumor tissue processing protocols in neuro-oncology: a perspective for gliomas and beyond.

Author

Rodriguez, Analiz, Ahluwalia, Manmeet S., Bettegowda, Chetan, Brem, Henry, Carter, Bob S., Chang, Susan, Das, Sunit, Eberhart, Charles, Garzon-Muvdi, Tomas, Hadjipanayis, Costas G., Hawkins, Cynthia, Jacques, Thomas S., Khalessi, Alexander A., McDermott, Michael W., Mikkelsen, Tom, Orr, Brent A., Phillips, Joanna J., Rosenblum, Mark, Shelton, William J., and Solomon, David A.

Subjects
INDIVIDUALIZED medicine, SURGICAL excision, GLIOMAS, OPERATING rooms, ADVISORY boards, BRAIN tumors
Abstract

Implementation of standardized protocols in neurooncology during the surgical resection of brain tumors is needed to advance the clinical treatment paradigms that use tissue for diagnosis, prognosis, bio-banking, and treatment. Currently recommendations on intraoperative tissue procurement only exist for diffuse gliomas but management of other brain tumor subtypes can also benefit from these protocols. Fresh tissue from surgical resection can now be used for intraoperative diagnostics and functional precision medicine assays. A multidisciplinary neuro-oncology perspective is critical to develop the best avenues for practical standardization. This perspective from the multidisciplinary Oncology Tissue Advisory Board (OTAB) discusses current advances, future directions, and the imperative of adopting standardized protocols for diverse brain tumor entities. There is a growing need for consistent operating room practices to enhance patient care, streamline research efforts, and optimize outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Immune Checkpoint Inhibitors in the Management of Brain Metastases from Non-Small Cell Lung Cancer: A Comprehensive Review of Current Trials, Guidelines and Future Directions.

Author

Ranjan, Tulika, Podder, Vivek, Margolin, Kim, Velcheti, Vamsidhar, Maharaj, Arun, and Ahluwalia, Manmeet Singh

Subjects
BRAIN tumor risk factors, CELLULAR signal transduction, IMMUNE checkpoint inhibitors, METASTASIS, MEDICAL research, DRUG efficacy, COMBINED modality therapy, LUNG cancer, PROGRESSION-free survival, BRAIN tumors, DISEASE complications
Abstract

Simple Summary: Immune checkpoint inhibitors (ICIs) have emerged as a promising treatment for brain metastases (BM) in non-small cell lung cancer (NSCLC), offering improved survival outcomes. Despite their potential, challenges remain due to the complex nature of BM and the need for combination therapies, including radiotherapy and anti-VEGF agents. This review discusses the current role of ICIs, the importance of optimizing treatment sequences, and the management of side effects. A personalized, multidisciplinary approach is essential for maximizing the benefits of ICIs in NSCLC patients with BM. Background: Brain metastases (BM) are a common, severe complication in patients with non-small cell lung cancer (NSCLC) and are difficult to treat due to their complex tumor biology and the intricate microenvironment of the brain. Objectives: This review examines the current role of immune checkpoint inhibitors (ICIs) in treating NSCLC with BM, focusing on the latest clinical trials, emerging strategies, current guidelines, and future directions. We highlight the efficacy of ICIs as monotherapy and in combination with other treatments such as radiotherapy, stereotactic radiosurgery, chemotherapy, and anti-VEGF agents. Results: While no single treatment sequence is universally accepted, combining ICIs with traditional therapies forms the core of the current treatment protocols. ICIs targeting the PD-1/PD-L1 pathway have significantly advanced NSCLC treatment, demonstrated by improved overall and progression-free survival in various settings. However, optimizing these benefits requires careful consideration of potential side effects, including cognitive decline and radiation necrosis, and the impact of steroid use on ICI efficacy. Conclusion: The review underscores the necessity for a personalized, integrated multidisciplinary treatment approach. Future research should focus on refining combination therapies and understanding the optimal sequence and timing of treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

39. State of Lung Cancer in Egypt: Moving Towards Improved Guidelines for Prevention, Screening, Treatment, and Clinical Care Programs

Author

Karim, Nagla Abdel, Rabea, Ahmed Magdy, Mack, Philip C., Subramanian, Janakiraman, Khalil, Ehab, Sherif, Mai, Marawan, Radwa, Gaafar, Tagrid, Shash, Lobna, Suzuki, Kei, Ahluwalia, Manmeet, Wahba, Hisham, Aboelela, Salma, Al Ahmadi, Asrar, Al Husaini, Hamed, Mohsen, Nada, Khaled, Rana, Kassem, Neemat, Khaled, Hussein, El Said, Noha, Zakhary, Nadia, Shoukry, Dina, ElSadieque, Alaa Abdullah, Alsedfy, M. Yasser, Islam, Shaheen, ElSherbiny, Hend, El Deftar, Mervat, Awad, Noha, Mohamed, Abdel Rahman, Gandara, David, Kelly, Karen, and Sen, Triparna

Published
2025
Full Text
View/download PDF

40. Multi-institutional validation of brain metastasis velocity, a recently defined predictor of outcomes following stereotactic radiosurgery

Author

McTyre, Emory R., Soike, Michael H., Farris, Michael, Ayala-Peacock, Diandra N., Hepel, Jaroslaw T., Page, Brandi R., Shen, Colette, Kleinberg, Lawrence, Contessa, Joseph N., Corso, Christopher, Chiang, Veronica, Henson-Masters, Adrianna, Cramer, Christina K., Ruiz, Jimmy, Pasche, Boris, Watabe, Kounosuke, D'Agostino, Ralph, Su, Jing, Laxton, Adrian W., Tatter, Stephen B., Fiveash, John B., Ahluwalia, Manmeet, Kotecha, Rupesh, Chao, Samuel T., Braunstein, Steve E., Attia, Albert, Chung, Caroline, and Chan, Michael D.

Published
2020
Full Text
View/download PDF

45. Neutrophil to lymphocyte ratio influences impact of steroids on efficacy of immune checkpoint inhibitors in lung cancer brain metastases

Author

Lauko, Adam, Thapa, Bicky, Sharma, Mayur, Muhsen, Baha’eddin, Barnett, Addison, Rauf, Yasmeen, Borghei-Razavi, Hamid, Tatineni, Vineeth, Patil, Pradnya, Mohammadi, Alireza, Chao, Samuel, Murphy, Erin S., Angelov, Lilyana, Suh, John, Barnett, Gene H., Nowacki, Amy S., Pennell, Nathan, and Ahluwalia, Manmeet S.

Published
2021
Full Text
View/download PDF

46. Author Correction: Neutrophil to lymphocyte ratio influences impact of steroids on efficacy of immune checkpoint inhibitors in lung cancer brain metastases

Author

Lauko, Adam, Thapa, Bicky, Sharma, Mayur, Muhsen, Baha’eddin A., Barnett, Addison, Rauf, Yasmeen, Borghei‑Razavi, Hamid, Tatineni, Vineeth, Patil, Pradnya, Mohammadi, Alireza, Chao, Samuel, Murphy, Erin S., Angelov, Lilyana, Suh, John, Barnett, Gene H., Nowacki, Amy S., Pennell, Nathan, and Ahluwalia, Manmeet S.

Published
2021
Full Text
View/download PDF

48. The landscape of cancer-associated transcript fusions in adult brain tumors: a longitudinal assessment in 140 patients with cerebral gliomas and brain metastases.

Author

Metellus, Philippe, Camilla, Clara, Bialecki, Emilie, Beaufils, Nathalie, Vellutini, Christine, Pellegrino, Eric, Tomasini, Pascale, Ahluwalia, Manmeet S., Mansouri, Alireza, Nanni, Isabelle, and Ouafik, L'Houcine

Subjects
GENE fusion, BRAIN metastasis, PROTEIN-tyrosine kinases, NUCLEOTIDE sequencing, GLIOBLASTOMA multiforme, BRAIN tumors
Abstract

Background: Oncogenic fusions of neurotrophic receptor tyrosine kinase NTRK1, NTRK2, or NTRK3 genes have been found in different types of solid tumors. The treatment of patients with TRK fusion cancer with a first-generation TRK inhibitor (such as larotrectinib or entrectinib) is associated with high response rates (>75%), regardless of tumor histology and presence of metastases. Due to the efficacy of TRK inhibitor therapy of larotrectinib and entrectinib, it is clinically important to identify patients accurately and efficiently with TRK fusion cancer. In this retrospective study, we provide unique data on the incidence of oncogenic NTRK gene fusions in patients with brain metastases (BM) and gliomas. Methods: 140 samples fixed and paraffin-embedded tissue (FFPE) of adult patients (59 of gliomas [17 of WHO grade II, 20 of WHO grade III and 22 glioblastomas] and 81 of brain metastasis (BM) of different primary tumors) are analyzed. Identification of NTRK gene fusions is performed using next-generation sequencing (NGS) technology using Focus RNA assay kit (Thermo Fisher Scientific). Results: We identified an ETV6 (5)::NTRK3 (15) fusion event using targeted next-generation sequencing (NGS) in one of 59 glioma patient with oligodendroglioma-grade II, IDH-mutated and 1p19q co-deleted at incidence of 1.69%. Five additional patients harboring TMPRSS (2)::ERG (4) were identified in pancreatic carcinoma brain metastasis (BM), prostatic carcinoma BM, endometrium BM and oligodendroglioma (grade II), IDH-mutated and 1p19q co-deleted. A FGFR3 (17)::TACC3 (11) fusion was identified in one carcinoma breast BM. Aberrant splicing to produce EGFR exons 2-7 skipping mRNA, and MET exon 14 skipping mRNA were identified in glioblastoma and pancreas carcinoma BM, respectively. Conclusions: This study provides data on the incidence of NTRK gene fusions in brain tumors, which could strongly support the relevance of innovative clinical trials with specific targeted therapies (larotrectinib, entrectinib) in this population of patients. FGFR3 (17)::TACC3 (11) rearrangement was detected in breast carcinoma BM with the possibility of using some specific targeted therapies and TMPRSS (2)::ERG (4) rearrangements occur in a subset of patients with, prostatic carcinoma BM, endometrium BM, and oligodendroglioma (grade II), IDH-mutated and 1p19q co-deleted, where there are yet no approved ERGdirected therapies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

49. Executive summary of the American Radium Society appropriate use criteria for brain metastases in epidermal growth factor receptor mutated-mutated and ALK-fusion non-small cell lung cancer.

Author

Nagpal, Seema, Milano, Michael T, Chiang, Veronica L, Soltys, Scott G, Brackett, Alexandria, Halasz, Lia M, Garg, Amit K, Sahgal, Arjun, Ahluwalia, Manmeet S, Tom, Martin C, Palmer, Joshua D, Knisley, Jonathan P S, Chao, Samuel T, Gephart, Melanie Hayden, Wang, Tony J C, Lo, Simon S, and Chang, Eric L

Published
2024
Full Text
View/download PDF

50. Systematic Review of Cerebrospinal Fluid Biomarker Discovery in Neuro-Oncology: A Roadmap to Standardization and Clinical Application.

Author

Mikolajewicz, Nicholas, Yee, Patricia P., Bhanja, Debarati, Trifoi, Mara, Miller, Alexandra M., Metellus, Philippe, Bagley, Stephen J., Balaj, Leonora, de Macedo Filho, Leonardo J.M., Zacharia, Brad E., Aregawi, Dawit, Glantz, Michael, Weller, Michael, Ahluwalia, Manmeet S., Kislinger, Thomas, and Mansouri, Alireza

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results